Chi-Med
Michael Shi has accumulated extensive experience in the pharmaceutical industry, starting as a Senior Director at Novartis in 2005. Michael then went on to become the Executive Vice President, Global Head of Research and Development at Transcenta in 2021. Currently, Michael serves as the Head of R&D and CMO at HUTCHMED since August 2022.
Michael Shi attended the University of Southern California from 1989 to 1994. No specific degree or field of study was mentioned.
This person is not in any teams
This person is not in any offices
Chi-Med
Hutchison China MediTech, or Chi-Med, is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma, focuses on discovering and deve...